XTX Topco Ltd Has $3.20 Million Holdings in Haleon PLC Sponsored ADR $HLN

XTX Topco Ltd grew its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 54.9% during the 2nd quarter, Holdings Channel reports. The firm owned 308,824 shares of the company’s stock after purchasing an additional 109,476 shares during the period. XTX Topco Ltd’s holdings in Haleon were worth $3,203,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of HLN. Wellington Management Group LLP lifted its holdings in Haleon by 22.0% in the first quarter. Wellington Management Group LLP now owns 18,700,480 shares of the company’s stock valued at $192,428,000 after buying an additional 3,372,155 shares during the period. Sculptor Capital LP raised its position in shares of Haleon by 22.1% during the 1st quarter. Sculptor Capital LP now owns 10,849,868 shares of the company’s stock valued at $111,645,000 after acquiring an additional 1,962,770 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Haleon by 15.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,776,686 shares of the company’s stock valued at $91,014,000 after acquiring an additional 1,174,813 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Haleon by 6.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 7,857,196 shares of the company’s stock valued at $81,479,000 after purchasing an additional 476,823 shares during the period. Finally, Nuveen LLC bought a new position in shares of Haleon in the 1st quarter worth $58,870,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on HLN shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a report on Wednesday, October 8th. The Goldman Sachs Group upgraded Haleon from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 10th. Finally, Barclays cut Haleon from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Haleon has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Trading Up 1.5%

NYSE HLN opened at $9.82 on Wednesday. The stock’s 50-day moving average is $9.27 and its 200-day moving average is $9.86. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63. Haleon PLC Sponsored ADR has a one year low of $8.71 and a one year high of $11.42. The firm has a market cap of $43.71 billion, a P/E ratio of 25.17, a P/E/G ratio of 2.96 and a beta of 0.20.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.